Delveinsight

DECEMBER 23, 2020

As per the Food Allergy Research & Education, in the US, each year, around 200,000 people require emergency medical care for allergic reactions to food. Food allergy is a specific immune response to certain food items that it considers harmful. What are the most common food allergies? Egg Allergy.

Allergies 52

Allergies Immune Response Production Development 52

Scienmag

DECEMBER 9, 2020

Scientists have developed the first poliovirus […].

Immune Response 75

Immune Response Vaccination Vaccine Scientist 75

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. Related: Red Meat Allergy Test Gets FDA Clearance. “We The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

pharmaphorum

SEPTEMBER 1, 2020

AstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across all adult age groups. The UK pharma said that the trial will recruit up to 30,000 adults aged 18 years or over to assess the safety, efficacy and immune response.

Vaccination 69

Vaccination Vaccine Trials Immune Response 69

XTalks

AUGUST 13, 2020

In a press statement , Kaiser Permanente outlined that in this phase of the trial, data will be collected about the safety, immune response and efficacy of the vaccine candidate as required for regulatory review.

Vaccination 89

Vaccination Vaccine Trials Clinical Trials 89

Scienmag

FEBRUARY 19, 2021

Preclinical tests at UAB last year showed potent systemic and mucosal immune responses in mice after a single intranasal dose. The vaccine candidate was developed by Maryland-based Altimmune Inc. Credit: UAB BIRMINGHAM, Ala. – The Altimmune Inc.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Scienmag

MARCH 19, 2021

Delivering vaccines directly to the lungs can boost immune responses to respiratory infections or lung cancer, study finds. MIT researchers have now developed a vaccination strategy that can create an army of T cells that are […].

Vaccination 48

Vaccination Vaccine Immune Response Development 48

The Pharma Data

SEPTEMBER 1, 2020

The company has been developing the vaccine in partnership with Oxford University, and has said it is recruiting up to 30,000 adults over the age of 18 across a broad spectrum of racial, ethnic and geographic groups who are healthy or have steady underlying conditions. . Conor Kavanagh. Source link.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

Pfizer

JULY 26, 2022

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. IMPORTANT SAFETY INFORMATION . has a fever.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

XTalks

AUGUST 16, 2021

Immune systems can be weakened in individuals with HIV/AIDS; cancer and transplant patients taking certain immunosuppressive drugs; and those with genetic diseases affecting the immune system like congenital agammaglobulinemia and congenital IgA deficiency. Related: CDC Backs J&J COVID-19 Shot Amid GBS and Delta Variant Concerns.

Vaccination 104

Vaccination Vaccine Antibody Immune Response 104

Scienmag

JULY 6, 2021

Researchers at Karolinska Institutet in Sweden publish new findings in the journal Cancer Discovery showing how pharmacological activation of the protein p53 boosts the immune response against tumours. Given its ability to react […].

Immune Response 40

Immune Response Protein Development Research 40

The Pharma Data

APRIL 3, 2021

Johnson & Johnson (the Company) has begun vaccinating adolescent participants in the ongoing Phase 2a clinical trial for its COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. Global Head, Janssen Research & Development, Johnson & Johnson. “In

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

XTalks

SEPTEMBER 21, 2023

The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. This groundbreaking endeavor has received support from the National Institute of Allergy and Infectious Diseases (NIAID).

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. The phase 1 study that is being run by the National Institute of Allergy and Infectious Diseases tests three dose levels of the vaccine, mRNA-1273, given in two injections a month apart in 120 adults.

Vaccination 53

Vaccination Vaccine Research Trials 53

Pfizer

JULY 19, 2022

The companies’ previously announced safety, tolerability and immunogenicity data from a Phase 2/3 trial that found a 30 µg booster dose of the Omicron-adapted bivalent vaccine candidate elicited a superior immune response against Omicron BA.1 is immunocompromised or are on a medicine that affects the immune system. has a fever.

Vaccination 100

Vaccination Vaccine Medicine Clinical Trials 100

The Pharma Data

SEPTEMBER 8, 2021

While these results are disappointing, w e believe th e rilzabrutinib clinical program holds great potential to address the unmet treatment needs of people living with immune-mediated diseases , ” said Naimish Patel, Head of Global Development, Immunology and Inflammation. “ Allergy, 75: 100-119. Arthritis Rheumatol.

Trials 52

Trials Immune Response Allergies Clinical Trials 52

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. INOVIO has assembled a global coalition of collaborators, partners and funders to rapidly advance the development of INO-4800. Department of Defense.

DNA 40

DNA Vaccination Vaccine Immune Response 40

Pfizer

JULY 8, 2022

Following a third dose in this age group , the vaccine was found to elicit a strong immune response, with a favorable safety profile similar to placebo. COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. has a fever. has bleeding disorder or is on a blood thinner.

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

Pfizer

JULY 8, 2022

COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. are immunocompromised or are on a medicine that affects the immune system. IMPORTANT SAFETY INFORMATION .

FDA Approval 102

FDA Approval Vaccination Vaccine Clinical Trials 102

The Pharma Data

NOVEMBER 17, 2020

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform. Since April 2020, Mymetics’ goal is to develop a safe and highly effective virosome-based Covid-19 vaccine that can be easily administered to all age groups, particularly to immune compromised and elderly populations.

Vaccination 40

Vaccination Vaccine Containment Development 40

The Pharma Data

JUNE 25, 2021

President of Research and Development, Novavax. government, including the Department of Defense, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Glenn, M.D., PREVENT-19 is being conducted with support from the U.S.

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

The Pharma Data

NOVEMBER 9, 2020

executive vice president of Research and Development at Amgen. AstraZeneca continues to lead development and Amgen continues to lead manufacturing. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles. Reese , M.D.,

Trials 52

Trials Production Sales Manufacturing 52

The Pharma Data

DECEMBER 21, 2020

executive vice president of Research and Development at Amgen. 4 Tezepelumab is being developed by AstraZeneca in collaboration with Amgen (see AstraZeneca and Amgen collaboration below). AstraZeneca continues to lead development and Amgen continues to lead manufacturing. Reese , M.D.,

Trials 40

Trials Production Sales Manufacturing 40

Pharmaceutical Technology

FEBRUARY 3, 2023

The failure of several late-stage trials highlights the challenging nature of HIV vaccine development. Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Scienmag

FEBRUARY 18, 2021

Researchers at the Ragon Institute of MGH, MIT and Harvard and Massachusetts General Hospital show that levels of specific antibodies developed in the immune response may influence COVID-19 outcomes in both children and adults.

Antibody 74

Antibody Immune Response Development Research 74

Scienmag

NOVEMBER 12, 2020

Inhaled delivery of a formulation of a key protein involved in the immune response – interferon beta-1a – to hospitalised COVID-19 patients in the UK reduced the odds that they would develop severe disease or die from SARS CoV-2 infection.

Immune Response 75

Immune Response Protein Clinical Trials Clinical Trials 75

Scienmag

SEPTEMBER 15, 2020

Credit: Michigan State University Differences in biological sex can dictate lifelong disease patterns, says a new study by Michigan State University researchers that links connections between specific hormones present before and after birth with immune response and lifelong immunological disease development.

Hormones 78

Hormones Immune Response Development Research 78

The Pharma Data

JULY 6, 2021

In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, M.D., 2) variants during the study period.

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

XTalks

NOVEMBER 30, 2023

Global entities such as the WHO, the Global Fund and the Joint United Nations Programme on HIV/AIDS (UNAIDS) have developed comprehensive strategies aligned with Sustainable Development Goal (SDG) target 3.3, These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV.

FDA Approval 111

FDA Approval Gene Therapy Gene Clinical Trials 111

Scienmag

JUNE 27, 2021

The first human trial has shown no obvious side effects and a good immune response. Hiroshi Kiyono, CC BY 4.0 A new vaccine to protect against deadly cholera has been made by grinding up genetically modified grains of rice. Researchers based […].

Vaccination 72

Vaccination Vaccine Immune Response Trials 72

XTalks

NOVEMBER 5, 2024

Proceeds from the IPO will fund preclinical and clinical development for Polyrizon’s innovative hydrogel product candidates, supporting further research and development (R&D). Trading began on the Nasdaq Capital Market under the ticker “PLRZ” on October 29, 2024.

Drug Delivery 111

Drug Delivery Drugs Immune Response Allergies 111

XTalks

MAY 17, 2024

Led by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID), World AIDS Vaccine Day emphasizes the importance of awareness and education in the fight against HIV/AIDS. Identified in the early 1980s, HIV quickly escalated into a global pandemic, spurring an urgent international response.

Vaccination 52

Vaccination Vaccine Research Immune Response 52

The Pharma Data

JULY 8, 2021

In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, M.D., 2) variants during the study period.

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

The Pharma Data

JULY 8, 2021

Tezepelumab is being developed by Amgen in collaboration with AstraZeneca. executive vice president of Research and Development at Amgen. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles.(24,25) Reese, M.D., About Tezepelumab.

Allergies 52

Allergies Trials In-Vivo Medicine 52

Pfizer

NOVEMBER 2, 2022

The vaccine candidate combines Pfizer’s quadrivalent modRNA-based influenza vaccine candidate, qIRV (22/23), which is currently in Phase 3 clinical development , and Pfizer and BioNTech’s authorized Omicron-adapted bivalent COVID-19 BNT162b2 (Original/Omicron BA.4/BA.5) The companies will share the development costs. Ugur Sahin, M.D.,

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

pharmaphorum

FEBRUARY 28, 2021

“Importantly, the vaccine was 100 percent effective in protecting against death from the disease everywhere it was tested,” commented Anthony Fauci, director of the National Institute for Allergy & Infectious Disease (NIAID). “To The vaccine causes the body to create its own copies of the protein, stimulating an immune response.

Vaccination 59

Vaccination Vaccine Immune Response Protein 59

pharmaphorum

SEPTEMBER 29, 2022

The disorder – driven by type 2 inflammation characterised by an antibody-based immune response – causes hard lumps or nodules to form on the skin that are so itchy they can lead patients to scratch themselves to the point of bleeding or pain. The post FDA clears Dupixent as first drug for rare skin disorder appeared first on.

Drugs 69

Drugs Immune Response Allergies Sales 69